Growth Hormone Replacement Found Safe for Long Term Use

Mark L. Hartman, M.D., presented the following report at the 12^th International Congress of Endocrinology. A group of 2,429 patients was followed for 2.3 years. 1,988 patients were treated with injectable human growth hormone (rHGH) replacement. They were compared to 441 similar patients who did not receive HGH. Bias was eliminated to insure that the treated and untreated groups were comparable except for  HGH replacement. Adverse events related to tumor growth and malignancy did not differ significantly between those treated and those not treated. Cardiovascular disease caused 36% of deaths in the treated group and 67% of deaths in the group that did not receive HGH. Cancer occurred  in 1.6% of the treated group and 2.7% of the untreated group. Statistical analysis did not reveal any significant difference in adverse events  between the treated and untreated groups.

Tucker ME. Growth hormone therapy appears safe in long term, 11-1-2004; Family Practice News; Volume 34, Number 21.

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

Insulin-like Growth Factor-1 (IGF-1, Somatomedin C) Blood Levels Are Not Associated With Prostate Specific Antigen (PSA) Levels or Prostate Cancer: A Study of 749 patients.  L. Cass Terry, M.D., Ph.D., Pharm.D., Medical College of Wisconsin, Milwaukee, WI. 53226 Chief Medical Officer, Cenegenics.  Click here to read another study of 749 men receiving HGH replacement therapy, showing no relationship with prostate cancer.

Mount Rainier Clinic
503 First Street South, Suite 1
Yelm, Washington 98597, USA

Telephone: (360) 458-1061
FAX: (360) 458-1661

email: Click here to send us an email message

Copyright © 2007 John A. Cranton, ARNP, all rights reserved

Last modified:                                           Disclaimer